Mark R. Busch

Represented EnSync, Inc. (NYSE American: ESNC), an alternative energy company, in connection with several public and private offerings of shares of common stock, convertible preferred stock, warrants, and convertible notes.

Represented Exact Sciences Corporation (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, in connection with a number of underwritten public offerings of common stock and convertible notes with total gross proceeds exceeding US$3 billion, and a number of acquisitions with aggregate purchase prices exceeding US$3 billion.

Represented Exact Sciences Corporation (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, in connection with issuance of US$500 million aggregate principal amount of a new series of 2.00% Convertible Senior Notes due 2030 in exchange for (i) US$183.7 million aggregate principal amount of existing 2027 Notes, (ii) US$200.9 million aggregate principal amount of existing 2028 Notes, and (iii) approximately US$138 million in cash.

Represented Exact Sciences Corporation (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, in acquiring all of the outstanding equity interests of PreventionGenetics, a Wisconsin-based genetic testing laboratory.

Represented Movano Inc. (NASDAQ: MOVE), a health technology company and maker of the Evie Ring, in connection with its initial public offering of shares of common stock on NASDAQ and multiple follow-on offerings, including underwritten public offerings and at-the-market financing transactions.

Represented Movano Health (NASDAQ: MOVE), a health technology company, with a $24.1 million private placement of common stock and warrants to a select group of investors that includes a tier-one multibillion-dollar medical device company, institutional and accredited investors, and members of the company's management team and board of directors.

Represented Movano Inc. (NASDAQ: MOVE), a health technology company and maker of the Evie Ring, with respect to an underwritten public offering of common stock with The Benchmark Company, LLC, a full-service investment banking firm, as the underwriter.

Represented MDxHealth SA (NASDAQ: MDXH), a commercial-stage precision diagnostics company, in its initial public offering and listing on NASDAQ and multiple follow-on offerings, including underwritten public offerings and at-the-market financing transactions.

Represented Cue Biopharma, Inc. (NASDAQ: CUE), an immunotherapy company, in connection with its initial public offering and listing on NASDAQ, and several follow-on at-the-market financing transactions.

Represented GQG Partners, Inc. (ASX: GQG), a global investment boutique focused on managing active equity portfolios, with respect to securities and corporate governance matters.

Represented CodeLogic, Inc., a software as a service provider, in connection with a number of private placement transactions.

Represented CLOCworks, Inc., a software as a service provider, in connection with a number of private placement transactions.

Represented a manufacturer of healthcare products with respect to a number of acquisitions.

Represented Energous Corporation (NASDAQ: WATT), a developer of wireless charging technology, in connection with its initial public offering and listing on NASDAQ, and several follow-on secondary financing transactions.

Represented ENDRA Life Sciences Inc. (NASDAQ NDRA), an ultrasound technology company, in connection with its initial public offering and listing on NASDAQ and multiple follow-on offerings, including bridge note financings, underwritten public offerings, and at-the-market financing transactions.